Clin Mol Hepatol.
2021 Jan;27(1):100-102. 10.3350/cmh.2020.0312.
Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
- 2Regenerative Medicine Research Center, Yonsei University Wonju College of Medicine, Wonju, Korea
- KMID: 2511458
- DOI: http://doi.org/10.3350/cmh.2020.0312
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison of Guidelines for Management of Chronic Hepatitis C
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
- Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
- Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
- Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
